Phase 1 N=88 Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
OSA · Sleep Apnea · Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index - Crossover — 34.9; 39.6 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=411 Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants
N/A N=648 First Heroes: Engaging Fathers in the First 1000 Days
Obesity, Childhood · Overweight and Obesity · Social Determinants of Health
Primary: Number of Infants With Rapid Infant Weight Gain — 12; 27 Participants
N/A N=27 Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors
Adolescent Cancer · Young Adult Cancer · Body Image
Primary: Feasibility of In-home Body Image (BI) -Focused Expressive Writing (EW) Intervention for Post-treatment Adolescent and Young Adult (AYA) Cancer Survivors With BI…
Phase 2 N=22 Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) · Pancreatic Ductal Adenocarcinoma
Primary: Study Drug-related Adverse Events — 3; 6; 3; 5 Participants
N/A N=161 A Patient-Centered Communication Tool (UR-GOAL) Versus Usual Care for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists
Acute Myeloid Leukemia
Primary: Shared Decision Making — 85.98; 86.55 Score on a Scale — p=0.85
Phase 2 N=58 GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Surrogate Biomarker of Oxidative Stress by Mass Spectroscopy — -79.9; 13.3 micromole/M tyrosine
Phase 4 N=922 Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
Chagas Disease · Heart Failure
Primary: Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From…
Phase 2 N=394 A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change From Baseline in Best-Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants — 7.1; 4.6; 5.5; 13.0 ETDRS letters…
N/A N=227 Novel Pharyngeal Metrics to Predict Dysphagia Outcomes
Dysphagia · Swallowing Disorders
Primary: pHRM Pressure Change (Pharyngeal) — 381; 395; 389; 402 mmHg·s·cm
Phase 3 N=573 A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Diabetes Mellitus, Type 2 · Obesity
Primary: Change in Glycated Haemoglobin (HbA1c) [Noninferiority] — -1.37; -0.65 Percentage point of HbA1c
Phase 2 N=66 Add-on Reparixin in Adult Patients With ARDS
Acute Respiratory Distress Syndrome, Adult
Primary: Change in Oxygenation Index (OI) From Baseline to Day 7 of Treatment — -5.3; -6.6 Index — p=0.735
Phase 2 N=77 A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
Psoriasis · Inflammation · Coronary Artery Disease
Primary: Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI) — -25.45; -18.95 Percentage change of score
N/A N=100 Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation
Haematological Malignancy
Primary: The Between-group Change for Body Weight — -4.0; -3.4 kilogram — p=0.24
N/A N=239 Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression
Depression · Unipolar Depression · Treatment Resistant Depression
Primary: Remission of Depression on the Hamilton Rating Scale for Depression-24 Item (HRSD-24) — 25; 30 Participants